Listen
BEXSERO (meningococcal group B vaccine) - Vaccine
Reason for request
Summary of opinion
Favourable opinion for maintenance of reimbursement for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B, in accordance with the HAS vaccine recommendations of 7 March 2024 and 27 June 2024.
Clinical Benefit
| Substantial |
The Committee deems that updating of the vaccine strategy in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical benefit, which remains substantial in the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. |
Clinical Added Value
| important |
The vaccine strategy update in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical added value in the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B (important clinical added value (CAV II) in individuals from the age of 2 months and older according to the opinion of 25 June 2014). |
